Pramlintide
Pramlintide, a peptide. Synthetic analog of human islet amyloid polypeptide (IAPP/amylin), with Pro substitutions at residues 25, 28, 29… Subcutaneous half-life 0.7 h.
Synthetic analog of human islet amyloid polypeptide (IAPP/amylin), with Pro substitutions at residues 25, 28, 29 to prevent the β-sheet aggregation that plagues native human amylin (but not rat amylin). Co-secreted physiologically with insulin. Activates AMY receptors (CT-R + RAMP1/2/3) in area postrema / brainstem → slowed gastric emptying, post-meal glucagon suppression, central satiety. Used as mealtime adjunct to insulin in T1D and insulin-treated T2D to flatten postprandial glucose and reduce meal-time insulin needs. Injected at separate SC site from insulin.
PK: McQueen 2005 (PMID:16278328) states "a mean elimination half-life of 30-50 minutes" in humans dosed subcutaneously. The stored 0.8 h (48 min) sat inside that range without being stated; 0.67 h is the midpoint, kept with the range quoted here so the spread is visible. ka 2 /h and V 21 L dropped 2026-09-06 — the abstract states neither, and no PubMed abstract gives a pramlintide volume. F is now carried as a LABEL citation rather than a PMID: the commonly used 30-40% comes from the approval document, and no indexed abstract states an absolute bioavailability for this peptide.
Pharmacokinetics
- Subcutaneous — t½ 40 min
Sources: PMID:16278328